Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL470424 | 0.94 | PTGS2 (0.89) | PTGS2PTGS1 | |
| SCHEMBL3822647 | 0.91 | PTGS2 (0.83) | PTGS2PTGS1 | |
| SCHEMBL15072534 | 0.90 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL15072535 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL15072551 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL15072423 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL470445 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL15072431 | 0.87 | PTGS2 (0.90) | PTGS2PTGS1 | |
| SCHEMBL15072574 | 0.86 | PTGS2 (0.76) | PTGS2PTGS1 | |
| SCHEMBL462393 | 0.86 | PTGS2 (0.76) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614050-B1 | 1,5-DIARYL-2-ALKYLPYRROLE-3-SUBSTITUTED NITRO ESTERS, SELECTIVE COX-2 INHIBITORS AND NITRIC OXIDE DONORS | Rottapharm Biotech Srl (IT) | 2016-01-20 | — | — | EP | disclosed |
| US-9162979-B2 | 1,5-Diary1-2-alkylpyrrole-3-substituted nitro esters, selective COX-2 inhibitors and nitric oxide donors | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-10-20 | — | — | US | disclosed |
| US-9162979-B2 | 1,5-Diary1-2-alkylpyrrole-3-substituted nitro esters, selective COX-2 inhibitors and nitric oxide donors | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-10-20 | — | — | US | disclosed |
| US-20130165494-A1 | 1,5-Diaryl-2-alkylpyrrole-3-Substituted Nitro Esters, Selective COX-2 Inhibitors and Nitric Oxide Donors | ROTTAPHARM S.P.A. (IT) | 2013-06-27 | — | — | US | disclosed |
| US-20130165494-A1 | 1,5-Diaryl-2-alkylpyrrole-3-Substituted Nitro Esters, Selective COX-2 Inhibitors and Nitric Oxide Donors | ROTTAPHARM S.P.A. (IT) | 2013-06-27 | — | — | US | disclosed |
| WO-2012032479-A1 | L,5-DIARYL-2-ALKVLPVRROLE-3-SUBSTITUTED NITRO ESTERS, SELECTIVE COX-2 INHIBITORS AND NITRIC OXIDE DONORS | ROTTAPHARM S.P.A. (IT) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165494-A1 | 1,5-Diaryl-2-alkylpyrrole-3-Substituted Nitro Esters, Selective COX-2 Inhibitors and Nitric Oxide Donors | NOS3, PTGER3, PTGES3 | PTGS2 9/4885PTGS1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.